Abstract
Antiretroviral (ARV) treatment interruptions are associated with virologic rebound, drug resistance, and increased morbidity and mortality. The Medicare Part D prescription drug benefit, implemented on January 1st, 2006, increased consumer cost-sharing. Consumer cost-sharing is associated with decreased access to medications and adverse clinical outcomes. We assessed the association of Part D implementation with treatment interruptions by studying 125 HIV-infected homeless and marginally housed individuals with drug coverage receiving ARV therapy. Thirty-five percent of respondents reported Medicare coverage and 11% reported ARV interruptions. The odds of ARV interruptions were six times higher among those with Part D coverage and remained significant after adjustment. The majority of Part D-covered respondents reporting ARV interruptions cited increased cost as their primary barrier. Directed interventions to monitor the long-term effects of increased cost burden on interruptions and clinical outcomes and to reduce cost burden are necessary to avoid preventable increases in morbidity and mortality.
Similar content being viewed by others
References
Adams, A. S., Soumerai, S. B., & Ross-Degnan, D. (2001). The case for a Medicare drug coverage benefit: A critical review of the empirical evidence. Annual Reviews of Public Health, 22, 49–61. doi:10.1146/annurev.publhealth.22.1.49.
Ammassari, A., Antinori, A., Aloisi, M. S., Trotta, M. P., Murri, R., Bartoli, L., et al. (2004). Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics, 45(5), 394–402. doi:10.1176/appi.psy.45.5.394.
Ammassari, A., Trotta, M. P., Murri, R., Castelli, F., Narciso, P., Noto, P., et al. (2002). Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. Journal of Acquired Immune Deficiency Syndromes, 31 Supplement 3, S123–S127.
Ananworanich, J., Gayet-Ageron, A., Le Braz, M., Prasithsirikul, W., Chetchotisakd, P., Kiertiburanakul, S., et al. (2006). CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the staccato randomised trial. Lancet, 368(9534), 459–465. doi:10.1016/S0140-6736(06)69153-8.
Bambauer, K. Z., Safran, D. G., Ross-Degnan, D., Zhang, F., Adams, A. S., Gurwitz, J., et al. (2007). Depression and cost-related medication nonadherence in Medicare beneficiaries. Archives of General Psychiatry, 64(5), 602–608. doi:10.1001/archpsyc.64.5.602.
Bangsberg, D. R., Ware, N., & Simoni, J. M. (2006). Adherence without access to antiretroviral therapy in sub-Saharan Africa? AIDS, 20(1), 140–141; author reply 141–142.. doi:10.1097/01.aids.0000196168.50303.31
Bozzette, S. A., Berry, S. H., Duan, N., Frankel, M. R., Leibowitz, A. A., Lefkowitz, D., et al. (1998). The care of HIV-infected adults in the United States. HIV Cost and services utilization study consortium. New England Journal of Medicine, 339(26), 1897–1904. doi:10.1056/NEJM199812243392606.
Cole, J. A., Norman, H., Weatherby, L. B., & Walker, A. M. (2006). Drug copayment and adherence in chronic heart failure: Effect on cost and outcomes. Pharmacotherapy, 26(8), 1157–1164. doi:10.1592/phco.26.8.1157.
Cook, J. A., Cohen, M. H., Burke, J., Grey, D., Anastos, K., Kirstein, L., et al. (2002). Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. Journal of Acquired Immune Deficiency Syndromes, 30(4), 401–409.
Cook, J. A., Grey, D., Burke-Miller, J., Cohen, M. H., Anastos, K., Gandhi, M., et al. (2006). Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women. AIDS Care, 18(2), 93–100. doi:10.1080/09540120500159284.
Cox, E. R., Jernigan, C., Coons, S. J., & Draugalis, J. L. (2001). Medicare beneficiaries’ management of capped prescription benefits. Medical Care, 39(3), 296–301. doi:10.1097/00005650-200103000-00009.
Danel, C., Moh, R., Minga, A., Anzian, A., Ba-Gomis, O., Kanga, C., et al. (2006). CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): A randomised trial. Lancet, 367(9527), 1981–1989. doi:10.1016/S0140-6736(06)68887-9.
El-Sadr, W. M., Lundgren, J. D., Neaton, J. D., Gordin, F., Abrams, D., Arduino, R. C., et al. (2006). CD4+ count-guided interruption of antiretroviral treatment. New England Journal of Medicine, 355(22), 2283–2296. doi:10.1056/NEJMoa062360.
Ellis, J. J., Erickson, S. R., Stevenson, J. G., Bernstein, S. J., Stiles, R. A., & Fendrick, A. M. (2004). Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Journal of General Internal Medicine, 19(6), 638–645. doi:10.1111/j.1525-1497.2004.30516.x.
Gibson, T. B., Mark, T. L., Axelsen, K., Baser, O., Rublee, D. A., & McGuigan, K. A. (2006a). Impact of statin copayments on adherence and medical care utilization and expenditures. American Journal of Managed Care, 12 Spec no., SP11-SP19.
Gibson, T. B., Mark, T. L., McGuigan, K. A., Axelsen, K., & Wang, S. (2006b). The effects of prescription drug copayments on statin adherence. American Journal of Managed Care, 12(9), 509–517.
Goldman, D. P., Joyce, G. F., & Zheng, Y. (2007). Prescription drug cost sharing: associations with medication and medical utilization and spending and health. Journal of the American Medical Association, 298(1), 61–69. doi:10.1001/jama.298.1.61.
Hall, J. P., Kurth, N. K., & Moore, J. M. (2007). Transition to Medicare Part D: An early snapshot of barriers experienced by younger dual eligibles with disabilities. American Journal of Managed Care, 13(1), 14–18.
Hays, R. D., Sherbourne, C. D., & Mazel, R. M. (1993). The RAND 36-Item Health Survey 1.0. Health Economics, 2(3), 217–227. doi:10.1002/hec.4730020305.
Headen, A. E., Jr., Masia, N. A., & Axelsen, K. J. (2006). Effects of Medicaid access restrictions on statin utilisation for patients treated by physicians practising in poor and minority neighbourhoods. Pharmacoeconomics, 24(Suppl 3), 41–53.
HIV Medicine Association. (2007). HIV Medical Provider Medicare Part D Survey.
Hosmer, D. L. S. (1989). Applied Logistic Regression. New York: John Wiley and Sons.
Hsu, J., Price, M., Huang, J., Brand, R., Fung, V., Hui, R., et al. (2006). Unintended consequences of caps on Medicare drug benefits. New England Journal of Medicine, 354(22), 2349–2359. doi:10.1056/NEJMsa054436.
Kaiser Family Foundation. (2005). Medicare chart book (3rd ed.). Menlo Park: Henry J. Kaiser Family Foundation.
Kaiser Family Foundation. (2006a). The role of Part D for people with HIV/AIDS: coverage and cost of antiretrovirals under Medicare drug plans (No. #7548). Menlo Park: Henry J. Kaiser Family Foundation.
Kaiser Family Foundation. (2006b). The Medicare prescription drug benefit. Menlo Park, CA: Kaiser Family Foundation.
Kaiser Family Foundation. (2006c). Dual eligibles: Medicaid’s role for low-income Medicare beneficiaries. Washington D.C.: Henry J. Kaiser Family Foundation.
Li, X., Margolick, J. B., Conover, C. S., Badri, S., Riddler, S. A., Witt, M. D., et al. (2005). Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. Journal of Acquired Immune Deficiency Syndromes, 38(3), 320–328.
Madden, J. M., Graves, A. J., Zhang, F., Adams, A. S., Briesacher, B. A., Ross-Degnan, D., et al. (2008). Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. Journal of the American Medical Association, 299(16), 1922–1928. doi:10.1001/jama.299.16.1922.
Mahoney, J. J. (2005). Reducing patient drug acquisition costs can lower diabetes health claims. American Journal of Managed Care, 11(5 Suppl), S170–S176.
Mojtabai, R., & Olfson, M. (2003). Medication costs, adherence, and health outcomes among Medicare beneficiaries. Health Affairs (Millwood), 22(4), 220–229. doi:10.1377/hlthaff.22.4.220.
Neuman, P., Strollo, M. K., Guterman, S., Rogers, W. H., Li, A., Rodday, A. M., et al. (2007). Medicare prescription drug benefit progress report: Findings from a 2006 national survey of seniors. Health Affairs (Millwood).
Oyugi, J. H., Byakika-Tusiime, J., Ragland, K., Laeyendecker, O., Mugerwa, R., Kityo, C., Mugyenyi, P., Quinn, T. C., & Bangsberg, D. R. (2007). Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS, 21, 1–7. doi:10.1097/QAD.0b013e32802e6bfa
Parienti, J. J., Massari, V., Descamps, D., Vabret, A., Bouvet, E., Larouze, B., et al. (2004). Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clinical Infectious Diseases, 38(9), 1311–1316. doi:10.1086/383572.
Rector, T. S., & Venus, P. J. (2004). Do drug benefits help Medicare beneficiaries afford prescribed drugs? Health Affairs (Millwood), 23(4), 213–222. doi:10.1377/hlthaff.23.4.213.
Reif, S., Whetten, K., Lowe, K., & Ostermann, J. (2006). Association of Unmet needs for support services with medication use and adherence among HIV-infected individuals in the Southeastern United States. AIDS Care, 18(4), 277–283. doi:10.1080/09540120500161868.
Robertson, M. J., Clark, R. A., Charlebois, E. D., Tulsky, J., Long, H. L., Bangsberg, D. R., et al. (2004). HIV seroprevalence among homeless and marginally housed adults in San Francisco. American Journal of Public Health, 94(7), 1207–1217.
Robinson, J. C. (2002). Renewed emphasis on consumer cost sharing in health insurance benefit design. Health Affairs (Millwood), Suppl Web Exclusives, W139–W154.
Robinson, J. C. (2004). Reinvention of health insurance in the consumer era. Journal of the American Medical Association, 291(15), 1880–1886. doi:10.1001/jama.291.15.1880.
Ruiz, L., Paredes, R., Gomez, G., Romeu, J., Domingo, P., Perez-Alvarez, N., et al. (2007). Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS, 21(2), 169–178. doi:10.1097/QAD.0b013e328011033a.
Schackman, B. R., Gebo, K. A., Walensky, R. P., Losina, E., Muccio, T., Sax, P. E., et al. (2006). The lifetime cost of current human immunodeficiency virus care in the United States. Medical Care, 44(11), 990–997. doi:10.1097/01.mlr.0000228021.89490.2a.
Shih, Y. C. (1999). Effect of insurance on prescription drug use by ESRD beneficiaries. Health Care Financing Review, 20(3), 39–54.
Soumerai, S. B., McLaughlin, T. J., Ross-Degnan, D., Casteris, C. S., & Bollini, P. (1994). Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine, 331(10), 650–655. doi:10.1056/NEJM199409083311006.
Spacek, L. A., Shihab, H. M., Kamya, M. R., Mwesigire, D., Ronald, A., Mayanja, H., et al. (2006). Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clinical Infectious Diseases, 42(2), 252–259. doi:10.1086/499044.
Starace, F., Ammassari, A., Trotta, M. P., Murri, R., De Longis, P., Izzo, C., et al. (2002). Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 31(Suppl 3), S136–S139.
Storch, E. A., Roberti, J. W., & Roth, D. A. (2004). Factor structure, concurrent validity, and internal consistency of the beck depression inventory—Second edition in a sample of college students. Depression and Anxiety, 19(3), 187–189. doi:10.1002/da.20002.
Stuart, B., & Zacker, C. (1999). Who bears the burden of Medicaid drug copayment policies? Health Affairs (Millwood), 18(2), 201–212. doi:10.1377/hlthaff.18.2.201.
Tamblyn, R., Laprise, R., Hanley, J. A., Abrahamowicz, M., Scott, S., Mayo, N., et al. (2001). Adverse events associated with prescription drug cost-sharing among poor and elderly persons. Journal of the American Medical Association, 285(4), 421–429. doi:10.1001/jama.285.4.421.
Tseng, C. W., Brook, R. H., Keeler, E., Steers, W. N., & Mangione, C. M. (2004). Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. Journal of the American Medical Association, 292(8), 952–960. doi:10.1001/jama.292.8.952.
van Servellen, G., Chang, B., Garcia, L., & Lombardi, E. (2002). Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care and STDS, 16(6), 269–281. doi:10.1089/10872910260066705.
Wilson, J., Axelsen, K., & Tang, S. (2005). Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. American Journal of Managed Care, 11 Spec No, SP27–SP34.
Zolopa, A. R., Hahn, J. A., Gorter, R., Miranda, J., Wlodarczyk, D., Peterson, J., et al. (1994). HIV and tuberculosis infection in San Francisco’s homeless adults. prevalence and risk factors in a representative sample. Journal of the American Medical Association, 272(6), 455–461. doi:10.1001/jama.272.6.455.
Acknowledgements
The authors thank Sheri Weiser M.D., M.P.H and Willi McFarland M.D., Ph.D. for their critical review of the manuscript and Christopher A. Douglas, J.D. for his Medicare Part D and health policy input. Funding Source: REACH Cohort study supported by NIMH 54907 and MD-D is supported by T32 MH19105. DRB receives support from NIAAA015287.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Das-Douglas, M., Riley, E.D., Ragland, K. et al. Implementation of the Medicare Part D Prescription Drug Benefit is Associated with Antiretroviral Therapy Interruptions. AIDS Behav 13, 1–9 (2009). https://doi.org/10.1007/s10461-008-9401-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-008-9401-5